Could removing metals boost chemo in leukemia?
NCT ID NCT06811233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether adding metal detoxification drugs (DMSA and Ca-EDTA) to standard therapy can improve outcomes for adults with intermediate- to high-risk acute myeloid leukemia (AML). Researchers believe lowering metal levels in blood and bone marrow may help control the disease or boost chemotherapy response. About 140 participants will be randomly assigned to receive detox therapy or standard care alone, with safety and side effects closely monitored.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- DMSA, Ca-EDTA, magnesium sulfate, and multivitamin
- What this could lead to
- If it works, this could point toward a way to improve chemotherapy response and disease control in AML by reducing metal levels in the body.
- What could go wrong
- This is an early phase 2 trial with only 140 participants, so results may not apply to all AML patients. The detox approach is experimental and may not improve outcomes or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA (AML) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas M. D. Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Can a new pill boost the power of an existing leukemia treatment?
- Can a new drug combo outperform standard care for a tough blood cancer?
- Can donor immune cells fight leukemia relapse after transplant?
- Can a liposomal chemo combo outsmart tough leukemias?
- Massive AML trial aims to find best chemo and transplant protection for younger patients